<?xml version='1.0' encoding='utf-8'?>
<document id="28506390"><sentence text="Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers."><entity charOffset="50-74" id="DDI-PubMed.28506390.s1.e0" text="omega-3 carboxylic acids" /><entity charOffset="91-103" id="DDI-PubMed.28506390.s1.e1" text="rosuvastatin" /><entity charOffset="108-119" id="DDI-PubMed.28506390.s1.e2" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.28506390.s1.e0" e2="DDI-PubMed.28506390.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s1.e0" e2="DDI-PubMed.28506390.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s1.e0" e2="DDI-PubMed.28506390.s1.e2" /><pair ddi="false" e1="DDI-PubMed.28506390.s1.e1" e2="DDI-PubMed.28506390.s1.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s1.e1" e2="DDI-PubMed.28506390.s1.e2" /></sentence><sentence text="Omega-3 carboxylic acids (OM3-CA) can lower triglyceride levels"><entity charOffset="0-24" id="DDI-PubMed.28506390.s2.e0" text="Omega-3 carboxylic acids" /><entity charOffset="26-32" id="DDI-PubMed.28506390.s2.e1" text="OM3-CA" /><entity charOffset="44-56" id="DDI-PubMed.28506390.s2.e2" text="triglyceride" /><pair ddi="false" e1="DDI-PubMed.28506390.s2.e0" e2="DDI-PubMed.28506390.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s2.e0" e2="DDI-PubMed.28506390.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s2.e0" e2="DDI-PubMed.28506390.s2.e2" /><pair ddi="false" e1="DDI-PubMed.28506390.s2.e1" e2="DDI-PubMed.28506390.s2.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s2.e1" e2="DDI-PubMed.28506390.s2.e2" /></sentence><sentence text=" OM3-CA is often prescribed concomitantly with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)"><entity charOffset="1-7" id="DDI-PubMed.28506390.s3.e0" text="OM3-CA" /></sentence><sentence text="" /><sentence text="The aim of the article was to assess the potential for pharmacokinetic interaction between OM3-CA and the statins rosuvastatin and simvastatin"><entity charOffset="114-126" id="DDI-PubMed.28506390.s5.e0" text="rosuvastatin" /><entity charOffset="131-142" id="DDI-PubMed.28506390.s5.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.28506390.s5.e0" e2="DDI-PubMed.28506390.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s5.e0" e2="DDI-PubMed.28506390.s5.e1" /></sentence><sentence text="" /><sentence text="Data from 2 phase I studies (ECLIPSE III and OM-EPA-007 [NCT01486433]) were analyzed" /><sentence text=" In ECLIPSE III, 59 participants received OM3-CA 4 g once daily for 13 days, with rosuvastatin 40 mg (single dose) co-administered with the 11th dose"><entity charOffset="82-94" id="DDI-PubMed.28506390.s8.e0" text="rosuvastatin" /></sentence><sentence text=" In OM-EPA-007, 52 participants received simvastatin 40 mg plus acetylsalicylic acid 81 mg daily for 14 days, with or without OM3-CA"><entity charOffset="4-14" id="DDI-PubMed.28506390.s9.e0" text="OM-EPA-007" /><entity charOffset="41-52" id="DDI-PubMed.28506390.s9.e1" text="simvastatin" /><entity charOffset="64-84" id="DDI-PubMed.28506390.s9.e2" text="acetylsalicylic acid" /><pair ddi="false" e1="DDI-PubMed.28506390.s9.e0" e2="DDI-PubMed.28506390.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s9.e0" e2="DDI-PubMed.28506390.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s9.e0" e2="DDI-PubMed.28506390.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28506390.s9.e1" e2="DDI-PubMed.28506390.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s9.e1" e2="DDI-PubMed.28506390.s9.e2" /></sentence><sentence text=" Lack of a drug-drug interaction was declared if the 90% confidence interval (CI) of the geometric least-squares mean ratio of pharmacokinetic parameters was in the range 80% to 125%" /><sentence text="" /><sentence text="For rosuvastatin, values for the geometric mean ratio (90% CI) with:without OM3-CA were 86"><entity charOffset="4-16" id="DDI-PubMed.28506390.s12.e0" text="rosuvastatin" /></sentence><sentence text="38% (80" /><sentence text="68-92" /><sentence text="48), 90" /><sentence text="50% (85" /><sentence text="99-95" /><sentence text="25), and 89" /><sentence text="01% (84" /><sentence text="30-93" /><sentence text="98), respectively, for maximum plasma concentration (Cmax), area under the concentration-time curve up to last measurable concentration (AUC0-t) and extrapolated to infinity (AUC0-inf)" /><sentence text=" Co-administration with a single dose of rosuvastatin did not affect the multiple-dose pharmacokinetics of constituent OM3-CA fatty acids eicosapentaenoic acid and docosahexaenoic acid"><entity charOffset="41-53" id="DDI-PubMed.28506390.s22.e0" text="rosuvastatin" /><entity charOffset="119-137" id="DDI-PubMed.28506390.s22.e1" text="OM3-CA fatty acids" /><entity charOffset="164-184" id="DDI-PubMed.28506390.s22.e2" text="docosahexaenoic acid" /><pair ddi="false" e1="DDI-PubMed.28506390.s22.e0" e2="DDI-PubMed.28506390.s22.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s22.e0" e2="DDI-PubMed.28506390.s22.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s22.e0" e2="DDI-PubMed.28506390.s22.e2" /><pair ddi="false" e1="DDI-PubMed.28506390.s22.e1" e2="DDI-PubMed.28506390.s22.e1" /><pair ddi="false" e1="DDI-PubMed.28506390.s22.e1" e2="DDI-PubMed.28506390.s22.e2" /></sentence><sentence text=" For simvastatin, values for steady state geometric mean ratio (90% CI) with:without OM3-CA were 91"><entity charOffset="5-16" id="DDI-PubMed.28506390.s23.e0" text="simvastatin" /></sentence><sentence text="61% (82" /><sentence text="82-101" /><sentence text="33) and 87" /><sentence text="47% (80" /><sentence text="19-95" /><sentence text="41), respectively, for Cmax and AUC0-t" /><sentence text=" No deaths or serious adverse events occurred in either trial" /><sentence text="" /><sentence text="OM3-CA can be administered with either rosuvastatin or simvastatin without affecting the pharmacokinetics of these statins"><entity charOffset="39-51" id="DDI-PubMed.28506390.s32.e0" text="rosuvastatin" /><entity charOffset="55-66" id="DDI-PubMed.28506390.s32.e1" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.28506390.s32.e0" e2="DDI-PubMed.28506390.s32.e0" /><pair ddi="false" e1="DDI-PubMed.28506390.s32.e0" e2="DDI-PubMed.28506390.s32.e1" /></sentence><sentence text="" /></document>